2,339 research outputs found
Mast Cells and Basophils: A Potential Link in Promoting Angiogenesis during Allergic Inflammation
Mast cells and basophils are granulated metachromatic cells which possess complex and partially overlapping roles in acquired and innate immunity, including both effector and regulatory activities. Mast cells and basophils cooperate in exacerbating and/or modulating inflammation as well as in mediating subsequent tissue repair. Mast cells release a series of potent proangiogenic molecules during inflammation that stimulate vessel sprouting and new vessel formation. Recent data suggest that basophils may also play a role in inflammation-related angiogenesis, principally but not exclusively through the expression of several forms of vascular endothelial growth factors and their receptors. This review focuses on the potential cooperative link between mast cells and basophils in promoting angiogenesis during allergic inflammation. We discuss the multifaceted roles of mast cells and basophils in inflammatory mechanisms of allergic diseases and whether these cells can be both source and target of proangiogenic mediators
A comprehensive biological and clinical perspective can drive a patient-tailored approach to multiple myeloma: Bridging the gaps between the plasma cell and the neoplastic niche
There is a broad spectrum of diseases labeled as multiple myeloma (MM). This is due not only to the composite prognostic risk factors leading to different clinical outcomes and responses to treatments but also to the composite tumor microenvironment that is involved in a vicious cycle with the MM plasma cells. New therapeutic strategies have improved MM patients' chances of survival. Nevertheless, certain patients' subgroups have a particularly unfavorable prognosis. Biological stratification can be subdivided into patient, disease, or therapy-related factors. Alternatively, the biological signature of aggressive disease and dismal therapeutic response can promote a dynamic, comprehensive strategic approach, better tailoring the clinical management of highrisk profiles and refractoriness to therapy and taking into account the role played by the MM milieu. By means of an extensive literature search, we have reviewed the state-of-the-art pathophysiological insights obtained from translational investigations of the MM-bone marrow microenvironment. A good knowledge of the MM niche pathophysiological dissection is crucial to tailor personalized approaches in a bench-bedside fashion. The discussion in this review pinpoints two main aspects that appear fundamental in order to gain novel and definitive results from the biology of MM. A systematic knowledge of the plasma cell disorder, along with greater efforts to face the unmet needs present in MM evolution, promises to open a new therapeutic window looking out onto the plethora of scientific evidence about the myeloma and the bystander cells
The anti-vegf(R) drug discovery legacy: Improving attrition rates by breaking the vicious cycle of angiogenesis in cancer
Resistance to anti-vascular endothelial growth factor (VEGF) molecules causes lack of response and disease recurrence. Acquired resistance develops as a result of genetic/epigenetic changes conferring to the cancer cells a drug resistant phenotype. In addition to tumor cells, tumor endothelial cells also undergo epigenetic modifications involved in resistance to anti-angiogenic therapies. The association of multiple anti-angiogenic molecules or a combination of anti-angiogenic drugs with other treatment regimens have been indicated as alternative therapeutic strategies to overcome resistance to anti-angiogenic therapies. Alternative mechanisms of tumor vasculature, including intussusceptive microvascular growth (IMG), vasculogenic mimicry, and vascular co-option, are involved in resistance to anti-angiogenic therapies. The crosstalk between angiogenesis and immune cells explains the efficacy of combining anti-angiogenic drugs with immune check-point inhibitors. Collectively, in order to increase clinical benefits and overcome resistance to anti-angiogenesis therapies, pan-omics profiling is key
Mammalian tumor xenografts induce neovascularization in zebrafish embryos.
The zebrafish (Danio rerio)/tumor xenograft model represents
a powerful new model system in cancer. Here, we describe a
novel exploitation of the zebrafish model to investigate tumor
angiogenesis, a pivotal step in cancer progression and target
for antitumor therapies. Human and murine tumor cell lines
that express the angiogenic fibroblast growth factor (FGF) 2
and/or vascular endothelial growth factor (VEGF) induce the
rapid formation of a new microvasculature when grafted close
to the developing subintestinal vessels of zebrafish embryos at
48 h postfertilization. Instead, no angiogenic response was
exerted by related cell clones defective in the production of
these angiogenic growth factors. The newly formed blood
vessels sprout from the subintestinal plexus of the zebrafish
embryo, penetrate the tumor graft, and express the transcripts
for the zebrafish orthologues of the early endothelial markers
Fli-1, VEGF receptor-2 (VEGFR2/KDR), and VE-cadherin.
Accordingly, green fluorescent protein–positive neovessels
infiltrate the graft when tumor cells are injected in transgenic
VEGFR2:G-RCFP zebrafish embryos that express green fluorescent
protein under the control of the VEGFR2/KDR
promoter. Systemic exposure of zebrafish embryos immediately
after tumor cell injection to prototypic antiangiogenic
inhibitors, including the FGF receptor tyrosine kinase inhibitor
SU5402 and the VEGFR2/KDR tyrosine kinase inhibitor
SU5416, suppresses tumor-induced angiogenesis without
affecting normal blood vessel development. Accordingly,
VE-cadherin gene inactivation by antisense morpholino
oligonucleotide injection inhibits tumor neovascularization
without affecting the development of intersegmental and
subintestinal vessels. These data show that the zebrafish/
tumor xenograft model represents a novel tool for investigating
the neovascularization process exploitable for drug
discovery and gene targeting in tumor angiogenesis
Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma
Ribatti D, Marzullo A, Gentile A, Longo V, Nico B, Vacca A & Dammacco F (2007) Histopathology 50, 591–596 Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinom
Nutraceuticals and their role in tumor angiogenesis
Angiogenesis plays a pivotal role in cancer initiation, maintenance, and progression. Diet may inhibit, retard or reverse these processes affecting angiogenesis (angioprevention). Nutraceuticals, such as omega-3 fatty acids, amino acids, proteins, vitamins, minerals, fibers, and phenolic compounds, improve health benefits as they are a source of bioactive compounds that, among other effects, can regulate angiogenesis. The literature concerning the pro-angiogenic and/or anti-angiogenic nutraceuticals and the possible activated pathways in cancer and other non-neoplastic diseases by in vivo and in vitro experiments are reviewed
AQP4 (aquaporin 4)
Review on AQP4 (aquaporin 4), with data on DNA, on the protein encoded, and where the gene is implicated
Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma
Ribatti D, Poliani P L, Longo V, Mangieri D, Nico B & Vacca A (2007) Histopathology50, 636–641 Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastom
Involvement of vascular endothelial growth factor in schizophrenia
Vascular endothelial growth factor (VEGF), which acts as an angiogenic and neurotrophic factor, is involved the regulation of cerebral blood volume and flow in Schizophrenia (SCZ). Several evidence indicates that modification of brain blood circulation due to alterations in the VEGF system affects cognitive performance and brain function in patients with SCZ. The aim of this study is: 1) To analyze the literature data concerning the role of VEGF in modulating the angiogenic response in SCZ. These data are controversial because some studies found elevated VEGF serum levels of VEGF in patients with SCZ, whereas others demonstrated no significant differences between SCZ patients and controls. 2)To analyze the role of VEGF as a predictive factor on the effects of antipsychotics agents used in the treatment of SCZ. In this context, high VEGF levels, associated to better responses to antipsychotics, might be predictive of the use of first generation antipsycotic drugs, whereas low VEGF levels, expression of resistance to therapy, might be predictive for the use of second generation antipsycotic drugs
- …